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Abstract
Background: Polymorphic variants and mutations disrupting canonical splicing isoforms are among the leading
causes of human hereditary disorders. While there is a substantial evidence of aberrant splicing causing Mendelian
diseases, the implication of such events in multi-genic disorders is yet to be well understood. We have developed
a new tool (SpliceScan II) for predicting the effects of genetic variants on splicing and cis-regulatory
elements. The novel Bayesian non-canonical 5’GC splice site (SS) sensor used in our tool allows inference on non-
canonical exons.
Results: Our tool performed favorably when compared with the existing methods in the context of genes linked
to the Autism Spectrum Disorder (ASD). SpliceScan II was able to predict more aberrant splicing isoforms
triggered by the mutations, as documented in DBASS5 and DBASS3 aberrant splicing databases, than other
existing methods. Detrimental effects behind some of the polymorphic variations previously associated with
Alzheimer’s and breast cancer could be explained by changes in predicted splicing patterns.
Conclusions: We have developed SpliceScan II, an effective and sensitive tool for predicting the detrimental
effects of genomic variants on splicing leading to Mendelian and complex hereditary disorders. The method could
potentially be used to screen resequenced patient DNA to identify de novo mutations and polymorphic variants
that could contribute to a genetic disorder.
Background
Human pre-mRNA sequences are subjected to complex
multi-stage modifications by splicing, where frequent
variations in this process contribute to the proteome
diversity. During splicing the intronic sequences are
recognized and excised by the spliceosome, where the
relatively short exonic sequences are joined together to
form mature mRNA. The Splice Site (SS) signals at the
intronic 5’ end (donor) and 3’ end (acceptor, polypyrimi-
dine tract and the branch point) are necessary, but not
sufficient for accurate and efficient exon recognition by
the spliceosome [1,2]. Additional exon-proximal ele-
ments are required for proper recognition of weakly
defined or alternatively committed exons [3]. These cis-
acting elements include a repertoire of Exonic Splicing
Enhancers (ESEs) and Intronic Splicing Enhancers (ISEs)
along with a number of Exonic Splicing Silencers (ESSs)
and Intronic Splicing Silencers (ISSs). The evolutionary
fine-tuned antagonism between enhancing and silencing
elements leads to the proper splicing of human pre-
mRNAs. Mutations disrupting cis-acting elements and
SSs themselves, as well as mutations creating cryptic SSs
and cis-acting factor binding sites can lead to severe dis-
eases [4].
Mutations affecting alternative and constitutive spli-
cing play a major role in human hereditary disorders
[5]. More than 5,477 splicing mutations (as of July 2008)
have been documented in the HGMD database [6],
which makes this group of mutations one of the most
frequent disease-causing alterations. Databases DBASS5
[7] and DBASS3 [8] contain 431 and 283 well annotated
disease-causing aberrant splicing events, respectively. A
clear understanding of elements affecting splicing could
potentially aid diagnosis and development of novel ther-
apeutic strategies [9,10].
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human multi-exonic genes [11], it is important to
understand the key regulators of this process. The 5’GC
SSs, flanking <1% of human exons [12], were shown to
play an important role in the genesis of alternative spli-
cing in human genes [13] and were found to accumulate
in mammalian lineage [14]. The majority of 5’GC SS
sensors, i.e. computational procedures reporting how
well an oligonucleotide would play a role of a SS, built
up to date is based on weight matrices [12,15]. Being an
elusive signal, it is difficult to collect a representative
learning set that would facilitate building a stronger
model. The importance of proper modeling the 5’GC SS
comes from the observation that some mutations docu-
mented in DBASS5 [7], such as IVS27+3_6dup(GGGT)
(-96), IVS7+1G>T(-40), IVS9+1G>A(-45) and others
trigger use of cryptic non-canonical 5’GC SS. Despite of
the importance of this splicing signal only few splicing
prediction methods, such as GeneSequer [16] and Net-
Gene2 [17], are able to score non-canonical exons.
Human introns contain many decoy exons that are
similar to authentic exons, but are never committed by
the spliceosome and outnumber the real exons by an
order of magnitude [18]. The mechanisms that allow
accurate discrimination between decoy exons and their
authentic counterparts are poorly understood. Codon
sequence contained in coding exons have particular 3-
periodic compositional biases [19] that allow gene fin-
ders, such as GenScan[20] and HMMgene[21], stitching
putative coding exons in a frame-consistent fashion with
high accuracy [22]. However, methods that rely on pro-
tein coding potential features experience severe perfor-
mance loss when confronted with non-coding exons
[23,24]. On the other hand, human mutations frequently
create de novo cryptic exons with no apparent coding
potential leading to severe disorders caused by aberrant
splicing [7,8]. Therefore, tools are needed to explain the
effects of mutations in terms of signals associated with
splicing free of protein coding context [3].
Investigation whether prediction of SSs could be
accomplished without relying on protein coding poten-
tial started with simple tools such as SpliceView[25]
and GENIO[26]. The NetUTR[24] tool has been specifi-
cally constructed to predict SSs in 5’ untranslated
regions (UTRs), therefore addressing the problem of
splicing prediction without relying on protein coding
features. Maximum Entropy Sensor [27] has been found
to be one of the most sensitive diagnostic methods pre-
dicting the effects of mutations in human genes [7,8,28].
ExonScan[29], a tool built around the exon definition
model, combines the power of the Maximum Entropy
Sensor with the Logarithm of Odds (LOD) biases asso-
ciated with the previously reported ESEs [30], ESSs [29]
and poly-G runs (known ISEs [31]). Recent CRYP-SKIP
[32,33] tool is based on multivariate logistic discrimina-
tion procedure that distinguishes the two aberrant spli-
cing outcomes from DNA sequences. Bayesian SS
sensor [23], shown to outperform the Maximum
Entropy Sensor [34], is an integral part of the Spli-
ceScan tool [23], built around the SS definition model
supported by the enhancers predicted with the MHMMo-
tif tool [23] and various other previously reported
silencing and enhancing signals. The SpliceScan has
been found to be especially efficient on the test set of
short 5’ UTR fragments.
We introduce a new tool SpliceScan II built
around the exon definition model [1]. Unlike in previous
SpliceScan[23] method, the new tool has option of
displaying factors contributing to a score assigned to a
specific exon isoform thus informing medical practi-
tioners of possible changes in splicing commitment
caused by polymorphic variants and mutations. We have
used a much larger set of orthologous exons originating
from 23 Tetrapoda organisms to train the new splicing
model following an observation that the spliceosomal
and cis-acting factors stay mostly intact across verte-
brates [4,35-38], where the genes encoding well-known
RNA binding proteins involved in splicing regulation are
enriched with ultraconserved elements [39]. The Spli-
ceScan II tool is based on the Bayesian SS sensors,
and uses the novel set of enhancer and silencer elements
computationally predicted in Tetrapoda organisms [40].
Having a large collection of Tetrapoda orthologous
exons we were able to collect learning set of 5’GC SSs,
representative enough to train a new Bayesian 5’GC SS
sensor, used in our tool. We compared the performance
of our tool with other methods on gene fragments
a n n o t a t e di nD B A S S 5[ 7 ]a n dD B A S S 3[ 8 ]a n dg e n e
structures linked to Autism Spectrum Disorder (ASD).
We further evaluated the method by predicting the
effects on splicing for some of the previously reported
polymorphisms associated with Alzheimer’sa n dt h e
Breast cancer, suggesting possible mechanism causing
the disease predisposition associated with such variants.
Results and Discussion
Predicting aberrant splicing isoforms
As a first step, we predicted the effects of mutations on
splicing. Figure 1 shows an example of SpliceScan
II predicted aberrant splicing events induced by the
IVS2+2delC mutation causing familial arterial hyperten-
sion as annotated in DBASS5 [7]. Table 1 shows predic-
tion accuracies achieved by ExonScan[29], GenScan
[20] and SpliceScan II in context of the gene frag-
ments annotated in aberrant splicing databases [see
Additional File 1]. For a prediction to be scored as cor-
rect a tool should predict the exonic boundary change
the way it is annotated in the databases, i.e. the original
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from a mutation. In case of mutation creating a cryptic
exon, appearance of both 3’ and 5’ boundaries of a cryp-
tic exon have to be predicted correct. We compared
only the methods that predict a gene structure in terms
of exons, i.e. predicting which particular exon isoform is
preferentially used in as result of mutation.
Our tool was twice as accurate compared to other top
performing methods for gene splicing prediction, such
as GenScan[20]. This result clearly demonstrates the
performance improvement on gene fragments contain-
ing aberrant splicing isoforms when a method relies on
splicing factors and signals rather than protein coding
potential. The other ExonScan[29] method was not
able to predict many aberrants p l i c i n gi s o f o r m sm a i n l y
because of the limited sensitivity, as discussed in the fol-
lowing subsection.
SpliceScan II splicing prediction accuracy
We estimated the performance of various ab initio spli-
cing prediction methods with our web-based testing fra-
mework [34] using the test set [see Subsection
Constructing the test set]a sab e n c h m a r k .T h e
comparative performance of the SpliceScan II is
shown in Figure 2. The comparative performance of the
5’GC SS sensor on the set of gene structures containing
1,320 5’GC SSs [see Subsection Learning the model]i s
shown in Figure 3. In these experiments Sensitivity (Sn)
and Specificity (Sp) were calculated according to the for-
mulas
Sn
TE
AE
Sp
TE
PE
 ,
where TE is the number of accurately predicted exon
boundaries, AE is the number of annotated exon bound-
aries in the test set and PE is the number of predicted
exon boundaries.
The winning tool should be both sensitive and specific
when predicting exonic boundaries for various thresh-
olds. Our tool appeared to be twice as sensitive com-
pared to other similar NetUTR[24] and ExonScan[29]
methods (although at expense of much lower specifi-
city), which would allow scoring roughly twice as many
exonic isoforms. It has lesser sensitivity than the
Figure 1 An example SpliceScan II output predicting an effect of mutation. IVS2+2delC annotated in DBASS5 [7] as causing familial
pulmonary arterial hypertension [56], a single nucleotide deletion which disrupts a strong non-canonical 5’GC SS (shown as purple circle) and
causes activation of two cryptic alternatively committed canonical 5’SSs located -60 and -108 nucleotides upstream of the original SS. Here we
successfully predict an effect of mutation on the original allele shown in (A), where two alternatively used aberrant exonic isoforms activated as
shown in (B). SpliceScan II predicted 3’SSs are represented as black-and-white triangles, 5’SSs are black-and-white circles, predicted exons
are shown as blue rectangles. The more intense the color a displayed signal, the higher its predicted strength. In (C) we show an example of
SpliceScan II textual output listing factors contributing to non-canonical GC exon score assignment shown in (A).
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the objective of two methods is different. Our new tool
has the main focus to predict how certain internal exo-
nic isoforms get activated, rather than assigning prob-
abilistic scores to all putative SSs the way SpliceScan
[23] and NetUTR[24] do.
Characteristics of tools shown in Figure 2 emphasize
on comparative aspect of their performance, and do not
necessarily reflect the prediction quality in practical
cases. Intronic regions in our test set are long, which
negatively affects sensitivity vs. false positive rates (the
majority of false positive exons is predicted within
introns). It has also been a split-sample test design for
our tool, where we specifically removed the extended
exons associated with the test set from the learning set,
which has slightly detrimental effect on the SpliceS-
can II performance. The mutations causing aberrant
splicing events, as annotated in DBASS databases [7,8],
are normally located close to annotated exons, therefore
in real experiments area of focus would normally be
shifted to an annotated exon and surrounding context,
where performance of our and other methods would
certainly be higher than shown in Figure 2.
The 5’GC SS sensor outperforms the existing sensor
designs based on weight matrices [12,15] for sensitivity
values higher than 35%. The initial artifact in the trajec-
tory below 35% sensitivity could be explained by the fact
that 34.15% of 5’GC SSs are CAGGCAAGT and AAGG-
CAAGT, on which our sensor returns two predefined
normalized scores of 0.914 and 0.744, correspondingly.
Predicting variations in splicing induced by disease
associated SNPs
We have predicted number of changes in gene splicing
patterns induced by the polymorphic variations pre-
viously associated with predisposition to the breast can-
cer and Alzheimer’s as shown in [see Additional File 2
Tables S1 and S2]. Some of the predicted changes are
quite dramatic, but in general SNPs cause milder effect
compared to the effect of mutations [see Section Pre-
dicting aberrant splicing isoforms] where annotated SSs
routinely disappear or mutations create new cryptic
exons. Number of polymorphic variants, potentially
alternating composition of gene isoforms, was predicted
for the disease associated and randomly selected groups
of control SNPs are shown in Table 2.
Here we tried to rank the polymorphic variations
according to their possible destabilizing effect on spli-
cing. We reported [see Additional File 2 Tables S1 and
S2] polymorphic variations that change annotated exon
score more than 2%, which according to [41] could
cause increased exon skipping or retention compared to
the reference exon. According to Table 2 number of
such events induced by the disease associated SNPs is at
least 3.5 times higher compared to control SNP groups,
which suggests active role of the disease associated
SNPs in modulation of predicted exonic strengths.
These variations could indicate consequently different
splicing commitment patterns for the affected exonic
isoforms. Another class of events is the score change for
the exons overlapping with the annotated exon, which
according to [7,8,41] could disrupt mRNA inclusion pat-
terns for alternatively used exon isoforms sharing an
annotated boundary. According to Table 2 number of
such events induced by the disease associated SNPs is
also significantly increased compared to control SNP
groups, which suggests destabilizing role for many of
such changes listed in [see Additional File 2 Tables S1
and S2]. Similar splicing destabilizing effect could be
achieved by simply removing or creating additional exon
isoforms sharing a SS with an annotated exon and the
number of such predicted events induced by the disease
associated SNPs is also substantially increased compared
to controls. On the contrary, the number of poly-
morphic variations associated with creation of new cryp-
tic SSs or pseudo exon deletion is approximately the
same for the disease associated and control group of
SNPs, which suggests insignificant effect on splicing for
these classes of events.
Conclusions
Using the set of previously predicted cis-acting elements
we were able to construct a splicing simulator capable
of predicting exon score changes induced by mutations
and polymorphic variants thus elucidating possible
mechanism behind such variants leading to disorders
caused by aberrant splicing.
Table 1 Tools accuracy predicting the aberrant splicing events.
Prediction method Databases
DBASS5 [7] DBASS3 [8]
Correct Incorrect Accuracy Correct Incorrect Accuracy
ExonScan[29] 42 320 11.6% 8 117 6.4%
GenScan[20] 52 310 14.36% 21 104 16.8%
SpliceScan II 100 262 27.62% 40 85 32%
Interpretation of counts reported in the table could be found in [see Additional File 1].
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cing prediction methods, in context of genes linked to
ASD. SpliceScan II provided more accurate predic-
tion of aberrant splicing events, as documented in
DBASS5 [7] and DBASS3 [8], compared to existing
methods. Although the performance of our tool predict-
ing the effect of mutations triggering an aberrant spli-
cing is high compared to other methods, it could not be
used as a general ab initio gene structural annotation
method since the number of false positive predicted
exons is high, as could be seen in Figure 2, though the
fraction of reported false positives is comparable to
what reported by other similar methods. Therefore, the
most informative use of our method would evolve
screening of polymorphic variants for possible splicing
alternations in the context of known reference human
gene structures. To accomplish this task we have cre-
ated companion Autism Candidate Gene Map
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Figure 2 Sensitivity vs. False positive rate trajectories for various tools. The performance of Bayesian and Maximum entropy SS sensors is
compared with the performance of tools specifically built to predict the splicing pattern independent of protein coding context features. (A)
Trajectories for 5’SS (B) Trajectories for 3’SS.
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375 that contains such structures and known alternative
splicing variants for candidate ASD genes.
The reason the SpliceScan II is less specific (espe-
cially for higher sensitivity values) than previous Spli-
ceScan tool [23] is in the nature of classification
problem we address with new method. As could be seen
in Figure 4, the SpliceScan uses simple probabilistic
model of scoring putative 3’ SS, where confidence of the
putative 3’ SS raises since two strong complement 5’SSs
are located downstream. However, according to [7] 3’SS
w o u l du n l i k e l yt of o r me x o nw i t ha n yo ft h e5 ’ SSs
located downstream in such a way since physiologically
feasible 5’SS normally avoid strong competitors nearby.
Indeed, SpliceScan scoring for both putative 5’SSs
would be mediocre due to a conflict associated with
their closeness. However, this observation does not help
to predict which exonic isoform would be activated. To
Table 2 Number of predicted splicing events induced by the same number of disease associated and control SNPs
randomly selected from the loci of 238 genes linked to ASD.
Type of event 997 SNPs 539 SNPs
Alzheimer’s
associated
Control Ratio Breast cancer
associated
Control Ratio
Predicted exon corresponding to an annotated exon disappears 0 2 0 0 0 -
Predicted exon corresponding to an annotated exon changes a
score
43 12 3.58 11 2 5.5
Predicted exon sharing a SS with an annotated exon changes a
score
242 78 3.10 59 29 2.03
Predicted exon sharing a SS with an annotated exon disappears 23 4 5.75 6 1 6.00
New predicted cryptic exon is created sharing a SS with with an
annotated exon
26 9 2.89 5 1 5.00
Predicted exon disappears 50 49 1.02 30 17 1.76
New predicted cryptic exon is created 50 46 1.08 24 25 0.96
Comparison is made in context of known annotated reference exons. Not all the originally available SNPs associated with a disorder mapped to loci of protein
coding genes, therefore number of SNPs reported here is lower than originally obtained [see Subsection Constructing the test set].
Comparative 5’GC SS sensor performance
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Figure 3 5’GC SS Bayesian sensor performance compared with two existing 5’GC SS sensors [12,15]based on weight matrices.
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possible pairs of putative 3’SS and 5’SS located no
further than 400 nt apart to predict possible SSs utiliza-
tion. The number of pseudo exons formed this way out-
number the real exons by at least on order of
magnitude [18], which turns in a harder classification
task than simple SSs classification. For the weak SSs the
number of putative exons to be classified is in excess of
the number of weak SSs flanking them, which translates
to a lower specificity compared to simpler SSs scoring
methods.
Among the SNPs listed in dbSNP http://www.ncbi.nlm.
nih.gov/projects/SNP/ as located within a gene locus,
extended with 2 kb upstream and downstream flanks, only
1% are non synonymous variants [42]. The rarity of such
SNPs suggested search for other causative variants affect-
ing protein function through alternations in gene regula-
tion, where disruption in splicing regulation seems a
natural choice. Here we conducted search for causative
alternations under realistic assumption that not all the
SNPs associated with a disease are causative; chances are
high that these SNPs were linked with causative variants
located at the same haplotype. Moreover, associated var-
iants may have different mechanism of compromising gen-
ome integrity such as creating missense/nonsense variants
or affecting gene transcription regulatory elements. Never-
theless, we have been able to establish a number of poten-
tially disease-causing splicing alternations.
Detected potentially detrimental exon score changes
for disease associated SNPs are generally milder com-
pared to the predicted changes associated with muta-
tions annotated in DBASS databases [7,8]. We did not
predict any disease associated SNPs causing an anno-
tated exon to disappear, an event that would most likely
have highly detrimental consequences. Comparison to
the predicted changes associated with the same sized
control groups of randomly selected SNPs indicated that
disease-causing SNPs have pronounced excess in the
number of detected potentially splice-disrupting var-
iants. Careful examination of factors contributing to an
exon score variation could lead to a plausible explana-
tion of causative mechanisms behind the disease asso-
ciated SNPs.
The SpliceScan II is available online at http://spli-
cescan2.lumc.edu/. The 5’GC SS sensor and the standa-
lone SpliceScan II program could be found at
http://www.wyomingbioinformatics.org/~achurban/.
Methods
Sequence data collection and processing
A set of 2,333,379 Tetrapoda exons extended with 205 nt
flanks from adjacent introns has been obtained as pre-
viously described in [40].P s e u d o e x o n s ,w h i c hw e r e
defined here as regions located between decoy 3’ and 5’
SSs, were extracted from intronic sequences flanked by
two homology-based predicted exons in data set of human
and mouse gene structures as described in [23]. The decoy
3’ and 5’ SSs were predicted by the Bayesian SS sensor
[23]. The first and last 150 nt in every intronic sequence
were excluded to avoid statistical biases associated with
exon proximal ISEs/ISSs [43]. The sum of decoy 3’ and 5’
Bayesian SS sensor scores had to exceed 0.05, where the
score for each signal was on a continuous 0 to 1 scale. The
pseudoexon lengths were chosen to be longer than 5 nt
and less than 400 nt, where 99% of authentic internal
exons reside in this length range [41,44]. Flanking intronic
regions of 205 nt were required on both sides of pseudo
exons to estimate if any elements are associated with
pseudo SSs. Pseudo exons were also checked for unique-
ness and were discarded if either flanking regions of a
pseudo exon or surrounding intronic fragments were iden-
tical to those previously processed.
Through the literature search we have collected the
test set of 238 human genes previously linked to ASD
[see Additional File 3] as a sample representative collec-
tion of important human genomic regions with potential
implication in medical practice. We excluded all the
extended exons corresponding to ASD genes from the
learning set of SpliceScan II tool for the purposes
of split-sample performance testing. We constructed a
+
+
  S S   ’ 5   g n o r t S   S S   ’ 5   g n o r t S   S S   ’ 3
Figure 4 Hypothetical situation of scoring putative 3’SS with SpliceScanmethod, where both strong 5’SSs located downstream
positively affect the confidence of 3’SS.
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with the corresponding gene structural annotation. The
set contains 4,650 known canonical 5’ and 3’ SS pairs
flanking the internal exons that need to be predicted by
various methods.
Learning the model
The LOD curves were constructed for the enhancers/
silencers, previously reported in [40] [see Additional File
4], associated with the splicing signals of various
strengths, an example of such dependencies could be
seen in Figure 5. We followed the assumption that the
weak splicing signals are more likely to be supported by
the enhancing elements [30] and avoid silencers. In
order to find LOD characteristic we calculate
log
Pr ( () |)
Pr ( () |)
2
ob D i HSS
ob D i H SS 


 


 ,w h e r et h eq u a n t i t yProb(D|H)
is called the likelihood of the data D (in our case ISEs,
ISSs, ESEs, ESSs and competing SSs) under hypothesis
H, Prob(D
(i)|HSS) is a signal likelihood at location i next
to a SS and Prob(D
(i)|H-SS) is a signal likelihood at loca-
tion i next to a splice-like signal.
Exon definition score is found through combining of the
5’ and 3’ SSs strengths predicted by the Bayesian SS
sensor [23] converted to LOD score, the LOD score
associated with the exonic length for given SSs strength,
the LOD scores associated with the presence of the
strong splicing competitor signals in vicinity or inside of
an exon defined and LOD scores associated with the
enhancers/silencers. Steric constrains and geometry of
the molecular interactions dictate the optimal exonic
length distribution [1,45] where stronger SSs could sus-
tain tighter packing of the splicing factors and therefore
such exons are shorter as could be seen in Figure 6.
The LOD score for an exon of length Sizeexon flanked by
SSs of certain strength Strength5’SS and Strength3’SS are
measured on a discrete scale from 1 to 5 by Bayesian SS
sensor [23]) is calculated as
LODsize
PDFexon Strength SS Strength SS Sizeexon
PDF  log
( ’ , ’ ,)
2
53
u uniform





,
where PDFexon,( Strength5’SS, Strength3’SS ,Sizeexon)i st h e
Probability Density Function (PDF) of mixture of beta
distributions interpolating the exon histogram as shown
in Figure 6 and PDFuniform = 1 is the PDF of uniform
distribution associated with the length of a pseudo exon.
SS classification in our system follows Bayesian rule in
terms LOD [46]
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Figure 5 An example LOD profiles for various 5’SS ISEs/ISSs signals in vicinity of a weak 5’SS (with discrete score 1 out of 3 possible).
Signal AAGGTAA is a core part of a strong canonical 5’SS and therefore is substantially depleted in vicinity of true exonic boundaries as
potential competitor. The distinctive bell-shaped LOD profiles for GGGGTGGG and CGGGGGCG are from the well studied poly-G family of ISEs
[31], known to form quadruplex structures [57].
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Page 8 of 12Table 3 Frequencies of oligonucleotides playing role of 5’GC SSs versus frequency of decoy 5’GC SS-like
oligonucleotides in pre-mRNA sequences recordered for tetrapoda organisms.
Signal Counted as true SS in Vertebrates Counted as decoy SS in Vertebrates Bayesian posterior Normalized
CAGGCAAGT 3263 36400 0.082 0.914
AAGGCAAGT 3246 41193 0.073 0.744
GAGGCAAGT 1898 35375 0.051 0.609
ACGGCAAGT 143 4519 0.031 0.555
AAGGCGAGT 199 6570 0.029 0.546
CAGGCGAGT 231 8750 0.026 0.535
ATGGCAAGT 580 30928 0.018 0.514
TCGGCAAGT 64 3971 0.016 0.497
GAGGCGAGT 141 9746 0.014 0.491
CCGGCAAGT 62 4534 0.013 0.486
AAGGCAAGC 415 36154 0.011 0.474
TAGGCAAGT 398 34927 0.011 0.452
CGGGCAAGT 64 5963 0.011 0.440
AAGGCACGT 92 10006 0.009 0.436
CTGGCAAGT 304 34884 0.009 0.426
AAGGCAAGG 475 54694 0.009 0.405
AAGGCAAGA 517 61104 0.008 0.379
CAGGCAAGA 365 55964 0.006 0.356
CAGGCAAGG 351 55387 0.006 0.337
CAGGCAAGC 275 44919 0.006 0.321
GAGGCACGT 51 9371 0.005 0.312
AGGGCAAGT 175 32213 0.005 0.306
TTGGCAAGT 188 36674 0.005 0.297
AACGCAAGT 19 3870 0.005 0.291
GCGGCAAGT 20 4303 0.005 0.290
GAGGCAAGC 166 37252 0.004 0.285
CGCGCAAGC 5 1155 0.004 0.281
AAGGCAGGT 292 75658 0.004 0.273
CCGGCACGT 9 2455 0.004 0.265
CAGGCACGT 122 35158 0.003 0.262
CCGGCGAGT 7 2036 0.003 0.258
GAGGCATGT 114 33194 0.003 0.255
TCGGCGAGT 4 1184 0.003 0.252
CAGGCAGGT 271 81896 0.003 0.245
TAGGCGAGT 12 3855 0.003 0.238
ATGGCGAGT 18 5790 0.003 0.237
AAAGCAAGT 209 67530 0.003 0.231
ACGGCACGT 5 1617 0.003 0.225
AAGGCATGT 174 60195 0.003 0.220
AAGGCGCGT 5 1733 0.003 0.216
Here prior probability for 5’GC SS is P (SS) = 5.16 × 10
-5.
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The middle two terms in (1) are the LOD ratio asso-
ciated with the posterior probability score returned by
the Bayesian sensor [23] for the 3’ and 5’ SSs. The first
term in the sum (1) takes into account the evidence
provided by the enhancers/silencers and comes up with
a valid posterior LOD ratio.
To resolve LOD score contribution from overlapping
enhancing/silencing elements we have allocated two
sorted lists containing elements; one with positive LOD
scores and another with negative. We keep only the ele-
ments with the highest negative LOD scores if any over-
laps exist among silencers and with the highest positive
LOD score if any overlaps exist among the enhancers.
Such strategy allows scoring the overlapping elements
that are antipodes in their enhancing profiles [47]. This
way we can also choose between the shorter and longer
version of the predicted cis-acting elements sharing the
common prefix, relying only on elements contributing
the maximum absolute LOD score.
Our Bayesian 5’GC SS sensor has been constructed in a
manner similar to the canonical Bayesian 5’SS sensor [23],
which demonstrated the predictive performance superior
to other SS sensor designs. To construct the sensor, first
we have collected gene structures containing 1,320 5’GC
SS from homology based annotations of human and
mouse genomes (described in [23]) along with pre-mRNA
frequencies of decoy 5’GC SSs. The entire learning set of
23 Tetrapoda organisms confirmed 19,059 non-canonical
5’GC SSs. Since other organisms presented in UCSC mul-
tiple genome alignments, beyond human and mouse, had
poor genome annotations we amplified found decoy 5’GC
SS scores by the factor of 19 059
1 320 14 44 ,
, .  to approximate
decoy counts for the 23 tetrapods. Table 3 shows first 40
top-scoring 5’GC SS posterior probabilities calculated
according to the formula
PS S o l i g o
PS S Po l i g o S S
PS S Po l i g o S S P S S Po l
(| )
()( |)
()( |) ( )(


   i igo SS |) 
where P(SS) - prior probability of an oligonucleotide
to be 5’GC SS, P(-SS) - prior probability of an oligonu-
cleotide to be donor-like signal, P(oligo|SS) - likelihood
of oligonucleotide in case of 5’GC SS, P(oligo|-SS) - like-
lihood of oligonucleotide in case of 5’GC SS-like signal.
Since the 5’GC SSs are recognized by the standard U2
spliceosome [1] and are commonly interchangeable with
the canonical 5’ SSs [36], it is reasonable to assume they
share the common context. For that reason the splicing
signals predicted by the newly constructed Bayesian
5’GC SS sensor were placed in the same probabilistic
context of the normal 5’SSs, except for the different
initial LOD characteristic of the 5’GC SS sensor and
additional normalization histogram to specifically nor-
malized score for 5’GC SSs flanked exons.
Constructing the test set
We wanted to estimate a potential implication of disease
associated Single Nucleotide Polymorphisms (SNPs) on
splicing, since many such variants emerge from recently
conducted association studies. A mechanism by which
these variations influence a disorder predisposition
remains elusive in many cases. We have identified 1,481
SNPs that have been previously associated with Alzhei-
mer’s available through AlzGene database http://www.
alzforum.org/res/com/gen/alzgene/default.asp and the
literature sources cited at Alzheimer research forum
http://www.alzforum.org/ and the 716 SNPs that have
been previously associated with the breast cancer
[48-53] [see Additional File 3]. We batch downloaded
the sequences for the SNPs from the dbSNP http://
www.ncbi.nlm.nih.gov/projects/SNP/, BLASTN [54]
aligned these sequences against Ensembl genomic contig
sequences obtained from EBI Alternative Splicing Data-
base project http://www.ebi.ac.uk/asd/altsplice/humrel3.
html, processed the results and mapped the location of
SNPs to the genomic contig sequences. For the same
genomic sequences we predicted the gene structures
with BLAT [55] using the RefSeq mRNA sequences
ftp://ftp.ncbi.nih.gov/refseq/H_sapiens/mRNA_Prot. We
synchronized SpliceScan IIab initio splicing predic-
tions with the homology-based annotated exons and
reported changes induced by the polymorphic variations.
Sets of control SNPs were randomly selected from loci
of 238 genes linked to ASD [see Additional File 3].
Additional file 1: Report and analysis of mutations causing aberrant
splicing events reported in DBASS5 [7]and DBASS3 [8]databases.
Prediction accuracy for aberrant splicing events triggered by mutations is
reported for SpliceScan II, ExonScan[29] and GenScan[20] tools.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
22-S1.XLS]
Additional file 2: Predicted splicing variations caused by SNPs
previously associated with Alzheimer’s and the breast cancer.S N P s
previously associated with Alzheimer’s and breast cancer predicted to
change the pattern of splicing.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
22-S2.DOC]
Additional file 3: Genes linked to ASD, SNPs previously associated
with Alzheimer’s and breast cancer and control SNPs randomly
picked from loci of genes associated with ASD. SNPs previously
associated with Alzheimer’s and breast cancer and genes linked to ASD
were collected through literature search.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
22-S3.XLS]
Additional file 4: Splicing regulatory elements reported in [40]and
their statistical significance. Repertoire of exonic and intronic splicing
enhancer/silencer elements used in building of SpliceScan II tool.
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